Novartis Ag (NVS) Common Equity (2009 - 2025)
Novartis Ag recorded quarterly Common Equity of $46.5 billion in Q4 2025, up 10.69% quarter-over-quarter from $42.1 billion in Q2 2025, and up 5.68% year-over-year from $44.0 billion in Q4 2024.
Novartis Ag's Common Equity history runs 13 years deep, the most recent figure standing at $46.5 billion for Q4 2025.
- In Q4 2025, Common Equity rose 5.68% year-over-year to $46.5 billion; the TTM figure through Dec 2025 stood at $46.5 billion (up 5.68% YoY), while the FY2025 annual figure was $46.5 billion, up 5.68% from the prior year.
- Common Equity came in at $46.5 billion for Q4 2025 at Novartis Ag, up from $42.1 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $67.8 billion in Q2 2021 to a low of $41.9 billion in Q2 2024.
- A 5-year average of $52.8 billion and a median of $49.3 billion in 2023 frame the typical range for Common Equity.
- Across the five-year window, Common Equity soared 4879.56% in 2021 and retreated 21.33% in 2023, its largest moves.
- Novartis Ag's Common Equity stood at $67.8 billion in 2021, then decreased by 12.38% to $59.4 billion in 2022, then fell by 21.33% to $46.8 billion in 2023, then retreated by 5.78% to $44.0 billion in 2024, then gained by 5.68% to $46.5 billion in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $46.5 billion, $42.1 billion, and $44.0 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 31.20 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 81.19 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -6.61 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 20.10 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 21.78 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.55 Bn |
| Jun 30, 2025 | 42.05 Bn |
| Dec 31, 2024 | 44.05 Bn |
| Jun 30, 2024 | 41.90 Bn |
| Dec 31, 2023 | 46.75 Bn |
| Jun 30, 2023 | 51.93 Bn |
| Dec 31, 2022 | 59.42 Bn |
| Jun 30, 2022 | 59.42 Bn |
| Dec 31, 2021 | 67.82 Bn |
| Jun 30, 2021 | 67.82 Bn |
| Dec 31, 2020 | -1.42 Bn |
| Jun 30, 2020 | 56.67 Bn |
| Dec 31, 2019 | -4.66 Bn |
| Jun 30, 2019 | 51.50 Bn |
| Dec 31, 2018 | 78.70 Bn |
| Jun 30, 2018 | 76.90 Bn |
| Dec 31, 2017 | -100.00 Mn |
| Dec 31, 2016 | 74.89 Bn |
| Dec 31, 2015 | 77.12 Bn |
| Mar 31, 2010 | 55,216.00 |
| Dec 31, 2009 | 57,462.00 |
| Sep 30, 2009 | 53,313.00 |
| Jun 30, 2009 | 50,488.00 |
| Mar 31, 2009 | 46,228.00 |